


Recombinant antigens ChimChagas1 and ChimChagas2 for *Trypanosoma cruzi*




Chagas disease, caused by infection with the parasite *Trypanosoma cruzi*, is an endemic infection in Central and South America. It has been estimated to affect between 16 and 18 million people in Latin America alone, with a further 100 million considered at risk.

According to the Division for the Control of Tropical Diseases of the World Health Organization, Chagas disease is still considered an important world public health problem. Chagasic infection is diagnosed mostly when specific antibodies (Abs) against *T. cruzi* antigens (Ags) are detected in a patient's blood, by use of conventional serological methods, such as enzyme-linked immunosorbent assay (ELISA) and indirect hemmagglutination (IHA).

The majority of the commercially available ELISAs employ antigens obtained by lysis of epimastogote or trypomastigote forms of *T. cruzi*. These tests are sensitive but often fail to distinguish between *T. cruzi*-specific and *Leishmania* sp.-specific antibodies, thus leading frequently to false-positive results.

Rekom Biotech has developed two different recombinant chimeras as biomarkers of Chagas disease: RAG0093 and RAG0094 which contain different antigenic determinants.

REFERENCE	ANTIGEN	APPLICATION	PACK SIZE
RAG0093	ChimChagas1	ELISA, DAS-ELISA, CLIA, LF	0.1 mg to 1 mg; bulk
RAG0094	ChimChagas2	ELISA, DAS-ELISA, CLIA, LF	0.1 mg to 1 mg; bulk

 **Rekom Biotech's recombinant antigens ChimChagas1 (RAG0093) and Chimchagas2 (RAG0094) have a 100% success rate in evaluations for the development of a commercial diagnostic assay.**